The Partin table allows risk assessment for prostate cancer below cT2c, and the MSKCC provides survival and extent of disease probability using the history of androgen deprivation therapy and radiation therapy, age, PSA, Gleason score, and percentage of positive biopsy core. The gene discussed is KLK3; the disease is Familial prostate cancer.